Concentration of Micafungin in the blood during continuous renal replacement therapy
- Conditions
- Suspected or proven candida infection requiring parenteral antifungal therapyMedDRA version: 17.0Level: LLTClassification code 10042941Term: Systemic fungal infection NOSSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
- Registration Number
- EUCTR2012-000904-14-AT
- Lead Sponsor
- Medizinische Universität Wien
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Age 19 to 70 years
Suspected or proven candia infection requiring parenteral antifungal therapy
Continuous venovenous hemofiltration because of an acute renal failure
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 6
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 4
Exclusion Criteria
Known history of hypersensitivity to echinocandins.
An expected survival of less than three days.
Known alcohol dependency, epilepsy, pregnancy or liver failure.
Sooroesophagitis
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method